文献速递呼吸道感染

大环内酯类联合治疗社区获得性肺炎:机器学习支持的个体化决策

Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
PubMed 文献 · Eur Respir J · 2019-12-12

基于CAPNETZ前瞻性队列中6440例中重度住院CAP患者,经倾向性评分匹配后纳入4898例,用机器学习构建决策树,发现无心血管疾病或合并呼吸系统疾病且呼吸道分泌物白细胞高的患者可从大环内酯类治疗中获益,符合该建议者180天死亡率降低27%(OR 1.83, 95%CI 1.48-2.27; p<0.001),但需随机对照试验验证。

要点

  • 决策树基于慢性心血管病、慢性呼吸病及呼吸道分泌物白细胞计数。
  • 无心血管病或呼吸病伴高白细胞者可能从大环内酯类联合治疗中获益。
  • 符合治疗建议者180天死亡率降低27%,但需RCT验证后方可常规应用。

核心结论

  • 按简单决策树规则分层大环内酯类治疗可能显著降低中重度住院CAP患者死亡率。
  • 该规则在临床常规实施前需前瞻性随机对照试验确认。

研究设计与样本

  • 观察性、前瞻性、多国CAPNETZ研究,纳入6440例中重度住院(非ICU)CAP患者。
  • 经倾向性评分匹配后选取4898例,采用交叉验证方案进行机器学习分析。
  • 主要结局为180天生存率。

主要发现

  • 决策树包含慢性心血管病、慢性呼吸系统疾病及入组时呼吸道分泌物白细胞计数。
  • 无心血管疾病或合并呼吸系统疾病且呼吸道分泌物白细胞高的患者从大环内酯类治疗中获益。
  • 符合治疗建议者死亡率降低27%(OR 1.83, 95%CI 1.48-2.27; p<0.001),对比实际标准治疗。

关键数值与推荐

  • 决策树变量:慢性心血管病、慢性呼吸系统疾病、呼吸道分泌物白细胞计数。
  • 获益人群:无心血管疾病,或合并呼吸系统疾病且呼吸道分泌物白细胞高。
  • 符合建议者180天死亡风险降低27%(OR 1.83, 95%CI 1.48-2.27; p<0.001)。

临床怎么用

  • 对中重度住院CAP患者,可依据慢性心血管病、慢性呼吸病及呼吸道分泌物白细胞计数评估是否联合大环内酯类。
  • 无心血管病或呼吸病伴高白细胞者可能优先考虑大环内酯类联合治疗。
  • 该决策规则尚未经RCT验证,暂不宜作为常规临床路径推广。

局限性

  • 为观察性研究,存在未测量混杂可能。
  • 决策规则需前瞻性随机对照试验确认后方可临床常规实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available ex ante to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient. METHODS: We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival. RESULTS: We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48-2.27; p<0.001) compared to the observed standard of care. CONCLUSION: Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. König R, Cao X, Oswald M, et al. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. Eur Respir J. 2019. PMID: 31537702. doi:10.1183/13993003.00824-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。